Larry Zeitlin, president at Mapp Biopharmaceutical Inc., said he wasn't surprised when several companies – large and small – jumped into developing products to attack the Ebola virus when the outbreak struck in West Africa in 2014.
Unfortunately, some of those firms, like Chimerix Inc., Sarepta Therapeutics Inc. and Tekmira, which now goes by






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
